Farxiga
developed to target type 2 diabetes mellitus to support healthy blood glucose levels.
Strengths: 5 · 10mg
Where to Check Availability
Medicine details
- Alternative names
Forxiga
- Therapeutic class
SGLT2 Inhibitor
- Pharmacological class
SGLT2 Inhibitor
- Contraindications
hypersensitivity to dapagliflozin; dialysis patients
- Precautions and warnings
monitor for urinary tract infections; prevent dehydration
- Minor side effects
polyuria; thirst; genital tract infection
- Moderate side effects
hypoglycaemia; back pain
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
AstraZeneca
- Onset Time
1–2 hours
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
Diuretics
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: not recommended. Breastfeeding: not advised.
Serious side effects
diabetic ketoacidosis — requires immediate medical attention; necrotising fasciitis — requires immediate medical attention
Patient summary
developed to target type 2 diabetes mellitus to support healthy blood glucose levels.
Mechanism of action
This medicine inhibits the sodium-glucose cotransporter 2 in the kidney, which leads to increased excretion of glucose in the urine.
Farxiga
developed to target type 2 diabetes mellitus to support healthy blood glucose levels.
Editorial Notes
- Active ingredient(s): Dapagliflozin
- Listed indication(s): Type 2 Diabetes Mellitus, Chronic Heart Failure